MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category

Dallas, Texas, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, proudly announces that its highly anticipated oral Semaglutide weight loss treatment marketed and branded under the name ‘Slim,’ is now available for purchase on the Company’s website at www.MangoRx.com. The launch of this product marks a key milestone in MangoRx’s expansion into the rapidly growing weight loss and weight management category.

Read more at globenewswire.com